March 12, 2007

Johnson & Johnson Receives Subpoenas

NEW BRUNSWICK, N.J., March 12, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received separate subpoenas from the U.S. Attorney's Office in Philadelphia, the U.S. Attorney's Office in Boston and the U.S. Attorney's Office in San Francisco. The subpoenas relate to investigations by those three offices previously disclosed in SEC filings and directed, respectively, to sales and marketing of RISPERDAL by Janssen, TOPAMAX by Ortho-McNeil and NATRECOR by Scios -- each subsidiaries of Johnson & Johnson.

The subpoenas request information regarding Johnson & Johnson's corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs.

Johnson & Johnson will cooperate in responding to these requests.

SOURCE Johnson & Johnson

Jeffrey J. Leebaw, +1-732-524-3350, or Bill Price, +1-732-524-6623, both Media
Contacts; Louise Mehrotra, +1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, or
Lesley Fishman, +1-732-524-3922, all Investor Contacts

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX

Close window | Back to top

Copyright 2015 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.